The focus of the current agreement is to support the clinical phase and to gather a body of evidence on Olympus’s technology platforms used in combination with FG001.

The agreement has no initial payment and is non-exclusive. The terms of this agreement are not disclosed.

“We’re thrilled to partner with Olympus, a global leader in medical technology. This collaboration is an exciting step forward in advancing precision cancer surgery for head and neck cancer. By combining FluoGuide’s FG001 technology with Olympus’s imaging systems, we’re working to improve surgical precision and deliver better outcomes for patients with cancer,” says Morten Albrechtsen, CEO of FluoGuide.